Virbac Unveils Canine Cephalexin Tablet

Posted: Sept. 5, 2012, 8:05 p.m. EDT



Published:

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Archive »Read More

Too Many Veterinarians, or a Bubble Market?

How can a scientifically trained profession keep ignoring the facts of too many graduates chasing too few jobs with an ever increasing debt burden?

Former Head of ASPCA Takes Over at PIJAC

The pet industry reacts over the controversial decision to hire former ASPCA executive Edwin J. Sayres as president and CEO of the Pet Industry Joint Advisory Council.

K-State Offers New Course on Regulation of Animal Drugs, Vaccines

The course begins this fall and is available through distance learning or on the K-State Olathe campus.

Add your comment:

Events


Show More...